RZLTRezolute, Inc.

5.090USD+7.84%Mkt Cap: 490.13M $P/E:

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously ad…